Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 17;11(11):CD003690.
doi: 10.1002/14651858.CD003690.pub5.

Pharmaceutical interventions for emotionalism after stroke

Sabine Allida  1 , Allan House  2 , Maree L Hackett  1
Affiliations

Pharmaceutical interventions for emotionalism after stroke

Sabine Allida et al. Cochrane Database Syst Rev. .

Abstract

Background: Antidepressants may be useful in the treatment of abnormal crying associated with stroke. This is an update of a Cochrane Review first published in 2004 and last updated in 2019.

Objectives: To evaluate the benefits and harms of pharmaceutical treatment in people with emotionalism after stroke.

Search methods: We searched the Cochrane Stroke Group Register, CENTRAL, MEDLINE, Embase, four other databases, and three trials registers (May 2022).

Selection criteria: We included randomised controlled trials (RCTs) and quasi-RCTs comparing psychotropic medication to placebo in people with stroke and emotionalism (also known as emotional lability, pathological crying or laughing, emotional incontinence, involuntary emotional expression disorder, and pseudobulbar affect).

Data collection and analysis: Two review authors independently selected trials, assessed risk of bias, extracted data from all included trials, and used GRADE to assess the certainty of the body of evidence. We calculated the mean difference (MD) or standardised mean difference (SMD) for continuous data and the risk ratio (RR) for dichotomous data, with 95% confidence intervals (CIs). We assessed heterogeneity using the I2 statistic. The primary emotionalism measures were the proportion of participants achieving at least a 50% reduction in abnormal emotional behaviour at the end of treatment, improved score on the Center for Neurologic Study - Lability Scale (CNS-LS) or Clinician Interview-Based Impression of Change (CIBIC), or diminished tearfulness.

Main results: We did not identify any new trials for this update. We included seven trials with a total of 239 participants. Two trials had a cross-over design, but outcome data were not available from the first phase (precross-over) in an appropriate format for inclusion as a parallel randomised controlled trial (RCT). Thus, the results of the review are based on five trials with a total of 213 participants. It is uncertain whether fluoxetine increases the number of people who have a 50% reduction in emotionalism when compared to placebo (risk ratio (RR) 0.26, 95% CI 0.09 to 0.77; P = 0.02; 1 trial, 19 participants) because the certainty of evidence is very low. Sertraline may lead to little to no difference in Center for Neurologic Study - Lability Scale (CNS-LS) scores and Clinician Interview-Based Impression of Change (CIBIC) scores when compared to placebo (RR 0.20, 95% CI 0.03 to 1.50; P = 0.12; 1 trial, 28 participants; low-certainty evidence). Antidepressants probably increase the number of people who experience a reduction in tearfulness (RR 0.32, 95% CI 0.12 to 0.86; P = 0.02; 3 trials, 164 participants; moderate-certainty evidence). No trials were found that evaluated the impact of other pharmaceutical interventions. Only two trial authors systematically recorded and reported adverse events, resulting in limited data on the potential harms of treatment. Six trials reported death as an adverse event and found no difference between the groups (antidepressants versus placebo) in the number of deaths reported (RR 0.59, 95% CI 0.08 to 4.50; P = 0.61; 172 participants; moderate-certainty evidence). This review provides very low- to moderate-certainty evidence that antidepressants may reduce the frequency and severity of emotionalism. The included trials were small and had some degree of bias.

Authors' conclusions: Antidepressants may reduce the frequency and severity of crying or laughing episodes when compared to placebo, based on very low-certainty evidence. Our conclusions must be qualified by several methodological deficiencies in the trials and interpreted with caution despite the effect being very large. The effect does not seem specific to one drug or class of drugs. More reliable data are required before appropriate conclusions can be made about the treatment of post-stroke emotionalism. Future trialists investigating the effect of antidepressants in people with emotionalism after stroke should consider developing and using a standardised method to diagnose emotionalism, determine severity, and assess change over time; provide treatment for a sufficient duration and follow-up to better assess rates of relapse or maintenance; and include careful assessment and complete reporting of adverse events.

PubMed Disclaimer

Conflict of interest statement

SA: has declared that they have no conflict of interest. AH: has declared that they have no conflict of interest. MH: has declared that they have no conflict of interest.

Figures

1
1
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Pharmaceutical interventions versus placebo, Outcome 1: Emotionalism
1.2
1.2. Analysis
Comparison 1: Pharmaceutical interventions versus placebo, Outcome 2: Emotionalism: mean scores at end of treatment
1.3
1.3. Analysis
Comparison 1: Pharmaceutical interventions versus placebo, Outcome 3: Depression: 1. Mean scores at end of treatment
1.4
1.4. Analysis
Comparison 1: Pharmaceutical interventions versus placebo, Outcome 4: Depression: 2. Average change in scores between baseline and end of treatment
1.5
1.5. Analysis
Comparison 1: Pharmaceutical interventions versus placebo, Outcome 5: Cognitive functioning: mean scores at end of treatment
1.6
1.6. Analysis
Comparison 1: Pharmaceutical interventions versus placebo, Outcome 6: Activities of daily living: 1. Mean scores at end of treatment
1.7
1.7. Analysis
Comparison 1: Pharmaceutical interventions versus placebo, Outcome 7: Adverse events: 1. Death
1.8
1.8. Analysis
Comparison 1: Pharmaceutical interventions versus placebo, Outcome 8: Adverse events: 2. All
1.9
1.9. Analysis
Comparison 1: Pharmaceutical interventions versus placebo, Outcome 9: Adverse events: 3. Leaving the study early (including death)
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Andersen 1993 {published data only}
    1. Andersen G, Riis JO. Citalopram for post-stroke pathological crying. Lancet 1993;342(8875):837-9. - PubMed
    1. Andersen G, Vestergaard K, Riis JO. Citalopram for post-stroke pathological crying. Journal of Neurology 1994;241 Suppl 1:S81. - PubMed
    1. Andersen G, Vestergaard K, Riis JO. Pathological crying and emotional lability - a controlled study of citalopram - a SSRI. Canadian Journal of Neurological Sciences 1993;20 Suppl 4:S115.
    1. Andersen G, Vestergaard K, Riis JO. Post-stroke pathological crying or emotional affect treated with citalopram: a selective serotonin reuptake inhibitor. Acta Neurologica Scandinavica 1994;89:151.
    1. Flicker C, Anderson G. Citalopram treatment of poststroke patients: improvement of uncontrolled crying. Journal of the American Geriatrics Society 1998;46(9):S67.
Brown 1998 {published data only}
    1. Brown KW, Sloan RL, Pentland B. Fluoxetine as a treatment for post-stroke emotionalism. Acta Psychiatrica Scandinavica 1998;98(6):455-8. - PubMed
Burns 1999 {published data only}
    1. Burns A, Russell E, Stratton-Powell H, Tyrell P, O'Neill P, Baldwin R. Sertraline in stroke-associated lability of mood. International Journal of Geriatric Psychiatry 1999;14(8):681-5. - PubMed
    1. Burns A, Russell E, Stratton-Powell H. A pilot study to evaluate the efficacy of sertraline in the management of emotional lability following stroke. In: 151st Annual Meeting of the American Psychiatric Association, Toronto, Ontario, Canada, 30th May to 4th June. Toronto, Ontario, Canada: American Psychiatric Association, 1998.
Choi‐Kwon 2006 {published data only}
    1. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine improves the quality of life in patients with poststroke emotional disturbances. Cerebrovascular Diseases 2008;26(3):266-71. [PMID: ] - PubMed
    1. Choi-Kwon S, Choi J, Kwon SU, Kang DW, Kim JS. Fluoxetine is not effective in the treatment of poststroke fatigue: a double-blind, placebo-controlled study. Cerebrovascular Disease 2007;23(2-3):103-8. - PubMed
    1. Choi-Kwon S, Choi JM, Kwon DW, Kim JS. Fluoxetine improves QoL in patients with post-stroke emotional disturbances. International Journal of Stroke 2008;3(Suppl 1):405-6.
    1. Choi-Kwon S, Han SW, Kwon SU, Kang DW, Choi JM, Kim JS. Fluoxetine treatment in poststroke depression, emotional incontinence, and anger proneness: a double-blind, placebo-controlled study. Stroke 2006;37(1):156-61. [PMID: ] - PubMed
    1. Choi-Kwon S, Kwon SU, Kang DW, Kim JS. Fluoxetine improves the quality of life in patients with post-stroke emotional disturbances. Stroke 2009;40(4):e282. - PubMed
Murray 2005 {published and unpublished data}
    1. Murray V, Von Arbin M, Asberg M, Bartfai A, Berggren A, Landtblom A, et al. Double-blind placebo comparison of sertraline and placebo in stroke patients with depression. Data on file 2003.
    1. Murray V, Von Arbin M, Bartfai A, Berggren AL, Landtblom AM, Lundmark J, et al. Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression. Journal of Clinical Psychiatry 2005;66(6):708-16. [PMID: ] - PubMed
    1. Murray V, Von Arbin M, Varelius R, Olsson JE, Terent A, Samuelsson M, et al. Sertraline in poststroke depression: a controlled study. Stroke 2002;33(1):292.
Ohkawa 1989 {published data only}
    1. Ohkawa S, Mori E, Yamadori A. Treatment of pathological laughing with amitriptyline. Rinsho Shinkeigaku 1989;29(9):1183-5. - PubMed
Robinson 1993b {published data only}
    1. Parikh RM, Robinson RG, Lipsey JR, Price TR. Nortriptyline treatment of post-stroke emotional lability: a double blind study. Neurology 1989;39 Suppl 1:177.
    1. Robinson R. Additional data provided by author. Data on file 2003.
    1. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry 1993;150(2):286-93. - PubMed

References to studies excluded from this review

Aizawa 1977 {published data only}
    1. Aizawa T, Kase M, Kutsuzawa T, Hasegawa T, Sekimoto H, Omae T. Clinical evaluation on the effect of cyclandelate in the treatment of cerebrovascular diseases: double-blind comparative placebo-controlled clinical study with cinnarizine as a basic treatment. Rinsho Hyoka 1977;5(3):659-86.
Allen 2018 {published data only}
    1. Allen C, Zarowitz B, O'Shea T, Peterson E, Yonan C, Waterman F. Identification of pseudobulbar affect symptoms in the nursing home setting: development and assessment of a screening tool. Geriatric Nursing 2018;39(1):54-9. - PubMed
Atarashi 1988 {published data only}
    1. Atarashi J, Ohtomo E, Kogure K, Hirai S, Tazaki Y, Araki G, et al. Clinical utility of HYG-FAS in treatment of cerebrovascular disorders: multi-center double-blind study in comparison with hydergine tablet 2mg. Rinsho Hyoka 1988;16(3):425-86.
Bassi 1984 {published data only}
    1. Bassi S, Albizzati MG, Sbacchi M, Frattola L. Chronic cerebrovascular disorders: clinical study with cyclandelate. British Journal of Clinical Practice 1984;38:344-9. - PubMed
Chen 2010 {published data only}
    1. Chen YR, Huang YP, Lin SJ, Kuan TH, Lin CH. Effectiveness of quetiapine for poststroke pathological laughing: case report and review of literature. Clinical Neuropharmacology 2010;33(6):319-22. - PubMed
ChiCTR‐IPR‐15007651 2015 {published data only}
    1. ChiCTR-IPR-15007651. Comparison of effects of fluoxetine in different dose on the secondary prevention of patients in acute ischemic stroke: a randomized controlled trial. www.chictr.org.cn/showprojen.aspx?proj=12909 (first received 26 December 2015).
Colamonico 2012 {published data only}
    1. Colamonico J, Formella A, Bradley W. Psuedobulbar affect: burden of illness in the USA. Advances in Therapy 2012;29(9):775-98. - PubMed
D'Amico 2017 {published data only}
    1. D'Amico S, Alexander DN, Cutler AJ, Zorowitz RD, Davis CS, Shin P, et al. Safety and tolerability of dextromethorphan/quinidine in older patients. American Journal of Geriatric Psychiatry 2017;25(3 Suppl 1):S142.
Doody 2014 {published data only}
    1. Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al. Safety, tolerability and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with Alzheimer's Disease/Dementia: PRISM-II. Annals of Neurology 2014;76(Suppl 18):S99-S100.
EUCTR2004‐004803‐39‐DE 2006 {published data only}
    1. EUCTR2004-004803-39-DE. SAINT II (Stroke - Acute Ischemic - NXY Treatment) A double blind, randomized, placebo controlled, parallel group, multicenter, phase IIb/III study to assess the efficacy and safety of intravenous NXY-059 in acute ischemic stroke - SAINT-II. www.clinicaltrialsregister.eu/ctr-search/trial/2004-004803-39/results (first received 18 August 2005).
EUCTR2011‐005541‐12‐DK 2012 {published data only}
    1. EUCTR2011-005541-12-DK. Efficacy of escitalopram treatment in acute stroke and the role of specific genotypes in stroke. www.clinicaltrialsregister.eu/ctr-search/trial/2011-005541-12/DK (first received 27 February 2012).
EUCTR2011‐006130‐16‐SE 2014 {published data only}
    1. EUCTR2011-006130-16-SE. Establishing the effect(s) and safety of fluoxetine in non-depressed stroke patients initiated in the acute phase of stroke. www.clinicaltrialsregister.eu/ctr-search/trial/2011-006130-16/SE (first received 16 June 2014).
EUCTR2013‐002253‐30‐DK 2013 {published data only}
    1. EUCTR2013-002253-30-DK. Efficacy of citalopram treatment in acute stroke [Clinical Trials Register]. www.www.clinicaltrialsregister.eu/ctr-search/trial/2013-002253-30/DK (first received 9 September 2013).
Formella 2017a {published data only}
    1. Formella AE, Alexander DN, Cutler AJ, D'Amico S, Hammond FM, Sauve W, et al. Dextromethorpha/quinidine improved symptoms of pseudobulbar affect irrespective of concomitant antidepressant use. CNS Spectrums 2017;22(1):64-5.
Formella 2017b {published data only}
    1. Formella AE, Alexander DN, Cutler AJ, D'Amico S, Hammond FM, Sauve W, et al. Dextromethorphan/quinidine improved symptoms of pseudobulbar affect irrespective of concomitant antidepressant use. Neurology 2017;88 Suppl 1:1-2.
Kim 2017a {published data only}
    1. Kim JS. Management of post-stroke mood and emotional disturbances. Expert Review of Neurotherapeutics 2017;17(12):1179-88. - PubMed
Kim 2017b {published data only}
    1. Kim JS, Lee EJ, Chang DI, Park JH, Ahn SH, Cha JK, et al. The efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry 2017;4(1):33-41. - PubMed
    1. NCT01278498. The preventive effect of escitalopram on depression and related emotional disorders in acute stroke patients. clinicaltrials.gov/ct2/show/NCT01278498 (first received 19 January 2011).
Lawson 1969 {published data only}
    1. Lawson IR, MacLeod RD. The use of imipramine ("Tofranil") and other psychotropic drugs in organic emotionalism. British Journal of Psychiatry 1969;115(520):281-5. - PubMed
Lorwatanapongsa 2020 {published data only}
    1. Lorwatanapongsa S, Chompoonuch S, Pongpakdee S, Mayotarn S, Piyatanont K, Awaiwanont A. Randomized controlled trial of fluoxetine or placebo on quality of life after acute ischemic stroke (RTAF-QoL). In: 36th Annual Meeting, The Royal College of Physicians of Thailand. 2020.
Manzo 1998 {published data only}
    1. Manzo JF, Health RL, Blonder LX. The interpersonal management of crying among survivors of stroke. Sociological Spectrum 1998;18(2):161-84.
Moller 2007 {published data only}
    1. Moller M, Andersen G, Gjedde A. Serotonin 5HT1A receptor availability and pathological crying after stroke. Acta Neurologica Scandinavica 2007;116(2):83-90. - PubMed
Muller 1999 {published data only}
    1. Muller U, Murai T, Bauer-Wittmund T, Cramon DY. Paroxetine versus citalopram treatment of pathological crying after brain injury. Brain Injury 1999;13(10):805-11. - PubMed
Narushima 2002 {published data only}
    1. Narushima P, Kosier J, Robinson R. Preventing poststroke depression: a 12-week double-blind randomized treatment trial and 21-month follow-up. Journal of Nervous and Mental Disease 2002;190(5):296-303. - PubMed
NCT01278498 2011 {published data only}
    1. NCT01278498. The preventive effect of escitalopram on depression and related emotional disorders in acute stroke patients. clinicaltrials.gov/ct2/history/NCT01278498 (first received 18 January 2011).
NCT01799941 2013 {published data only}
    1. NCT01799941. Safety, tolerability and effectiveness of nuedexta in the treatment of pseudobulbar affect (PBA). clinicaltrials.gov/ct2/show/NCT01799941 (first received 27 February 2013).
Ohtomo 1985 {published data only}
    1. Ohtomo E, Kutsuzawa T, Araki G, Hirai S, Terashi A, Kuzuya F, et al. Clinical usefulness of tiapride on psychiatric symptoms caused by cerebrovascular disorders: a multi-center double-blind study in comparison with inactive placebo. Rinsho Hyoka 1985;13(2):295-332.
Otomo 1984 {published data only}
    1. Otomo E, Saso S, Araki G, Hirai S, Atarashi J, Hasegawa K, et al. Clinical evaluation of amantadine hydrochloride (Symmetrel) in the treatment of cerebrovascular disorders with psychiatric symptoms: multi-center double-blind study in comparison with placebo. Rinsho Hyoka 1984;12(2):321-67.
Rasmussen 2000 {published data only}
    1. Rasmussen A, Klysner R, Mellerup E. A double-blind, placebo-controlled study of the prophylactic effect of sertraline in post stroke emotional lability. Conference poster 2000.
    1. Rasmussen A, Lunde M, Poulsen DL, Sorensen K, Qvitzau S, Bech P. A double-blind, placebo-controlled study of sertraline in the prevention of depression in stroke patients. Psychosomatics 2003;44(3):216-21. - PubMed
    1. Rasmussen A. A double blind controlled study of the influence of sertraline on the incidence of post stroke depression and on emotional lability [PhD Thesis]. Copenhagen (Denmark): University of Copenhagen, 2000.
    1. Rasmussen A. Depression and stroke. Nordic Journal of Psychiatry 2001;55(4):288.
    1. Rasmussen A. Post-stroke emotional lability. A double-blind psychopharmacological treatment with sertralin. Nordic Journal of Psychiatry 2000;54:35.
Sauve 2017 {published data only}
    1. Sauve W, Alexander DN, Cutler AJ, D'Amico S, Hammond FM, Zorowitz RD, et al. Neurological and psychiatric comorbidities assessment in the PRISM II study of dextromethorphan/quinidine for treatment of pseudobulbar affect. CNS Spectrums 2017;22(1):104.
Schiffer 1985 {published data only}
    1. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. New England Journal of Medicine 1985;312(23):1480-2. - PubMed
Schoedel 2014 {published data only}
    1. Schoedel KA, Morrow SA, Sellers EM. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatric Disease and Treatment 2014;10:1161-74. - PMC - PubMed
Seliger 1992 {published data only}
    1. Seliger GM, Hornstein A, Flax J, Herbert J, Schroeder K. Fluoxetine improves emotional incontinence. Brain Injury 1992;6(3):267-70. - PubMed
Udaka 1984 {published data only}
    1. Udaka F, Yamao S, Nagata H, Nakamura S, Kameyama M. Pathologic laughing and crying treated with levodopa. Archives of Neurology 1984;41(10):1095-6. - PubMed
Work 2011 {published data only}
    1. Work SS, Colamonico JA, Bradley WG, Kaye RE. Pseudobulbar affect: an under-recognized and under-treated neurological disorder. Advances in Therapy 2011;28(7):586-601. - PubMed
Yang 2015 {published data only}
    1. Yang LPH, Deeks ED. Dextromethorphan/quinidine: a review of its use in adults with pseudobulbar affect. Drugs 2015;75(1):83-90. - PubMed

Additional references

Allman 1989
    1. Allman P. Crying and laughing after brain damage: a confused nomenclature. Journal of Neurology, Neurosurgery, and Psychiatry 1989;52(12):1439-40. - PMC - PubMed
Allman 1992a
    1. Allman P. Drug treatment of emotionalism following brain damage. Journal of the Royal Society of Medicine 1992;85(7):423-4. - PMC - PubMed
Allman 1992b
    1. Allman P, Marshall M, Hope A, Fairburn C. Emotionalism following stroke: development and reliability of a semi-structured interview. International Journal of Methods in Psychiatric Research 1992;2:125-31.
APA 1987
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IIIR. Washington, DC: American Psychiatric Association, 1987.
APA 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association, 1994.
APA 2017
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Arlington VA: American Psychiatric Publishing, 2017.
Beck 1961
    1. Beck AT, Ward C, Mendelson M. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-71. - PubMed
Benedek 1995
    1. Benedek D, Peterson KA. Sertraline for treatment of pathological crying. American Journal of Psychiatry 1995;152(6):953-4. - PubMed
Brookshire 1970
    1. Brookshire R. Control of "involuntary" crying behaviour emitted by a multiple sclerosis patient. Journal of Communication Disorders 1970;3(3):171-6.
Broomfield 2021
    1. Broomfield NM, West R, House A, Munyombwe T, Barber M, Gracey F, et al. Psychometric evaluation of a newly developed measure of emotionalism after stroke (TEARS-Q). Clinical Rehabilitation 2021;35(6):894-903. - PMC - PubMed
Calvert 1998
    1. Calvert T, Knapp P, House A. Psychological associations with emotionalism after stroke. Journal of Neurology, Neurosurgery and Psychiatry 1998;65(6):928-9. - PMC - PubMed
Deeks 2021
    1. Deeks JJ, Higgins JPT, Altman DG. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.
Fitzgerald 2021
    1. Fitzgerald S, Gracey F, Broomfield N. Post-stroke emotionalism (PSE): a qualitative longitudinal study exploring individuals' experience with PSE. Disability and Rehabilitation 2021 [Epub ahead of print]. [DOI: 10.1080/09638288.2021.2002439] - DOI - PubMed
Folstein 1975
    1. Folstein MF, Folstein SE, McHugh PR. 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research 1975;12(3):189-98. - PubMed
Gillespie 2016
    1. Gillespie D, Cadden AP, Lees R, West RM, Broomfield NM. Prevalence of psuedobulbar affect following stroke: a systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases 2016;25(3):688-94. - PubMed
Gillespie 2022
    1. Gillespie DC, Halai AD, West RM, Dickie DA, Walters M, Broomfield NM. Demographic, clinical and neuroimaging markers of post-stroke emotionalism: a preliminary investigation. Journal of the Neurological Sciences 2022;436:120229. - PubMed
Goldberg 1972
    1. Goldberg DP. The Detection of Psychiatric Illness by Questionnaire. Vol. 21. Oxford: Oxford University Press, 1972.
Gompertz 1993
    1. Gompertz P, Pound P, Ebrahim S. The reliability of stroke outcome measurement. Clinical Rehabilitation 1993;7(4):290-6.
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 28 April 2022. Available at gradepro.org.
Hamilton 1960
    1. Hamilton M. Rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62. - PMC - PubMed
Hanger 1993
    1. Hanger HC. Emotionalism after stroke. Lancet 1993;342(8881):1235-6. - PubMed
Higgins 2017
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from training.cochrane.org/handbook/archive/v5.2.
House 1989
    1. House A, Dennis M, Molyneux A, Warlow C, Hawton K. Emotionalism after stroke. BMJ 1989;298(6679):991-4. - PMC - PubMed
ICD 10
    1. World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992.
Kim 2000
    1. Kim JS, Choi-Kwon S. Post stroke depression and emotional incontinence. Neurology 2000;54(9):1805-10. - PubMed
Kim 2005
    1. Kim SW, Shin IS, Kim JM, Lim SY, Yang SJ, Yoon JS. Mirtazapine treatment for pathological laughing and crying after stroke. Clinical Neuropharmacology 2005;28(5):249-51. - PubMed
Klingbeil 2021
    1. Klingbeil J, Wawrzyniak M, Stockert A, Brandt M-L, Schneider H-R, Metelmann M, et al. Pathological laughter and crying: insights from lesion network-symptom-mapping. Brain 2021;144(10):3264-76. - PubMed
Knopman 1994
    1. Knopman D, Knapp MJ, Gracon SI, Davis CS. The Clinician Based Impression (CIBI): a clinician’s global change rating scale in Alzheimer’s disease. Neurology 1994;44:2315–21. - PubMed
Lauterbach 1991
    1. Lauterbach E, Schweri M. Amelioration of pseudobulbar affect by fluoxetine. Journal of Clinical Psychopharmacology 1991;11:392-3. - PubMed
Lawson 1969
    1. Lawson JR, Macleod RD. The use of imipramine ("Tofranil") and other psychotropic drugs in organic emotionalism. British Journal of Psychiatry 1969;115:281-5. - PubMed
Mahoney 1965
    1. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Maryland State Medical Journal 1965;14:61-5. - PubMed
Massey 1981
    1. Massey E, Lowe S. Lithium carbonate in pseudobulbar palsy. Annals of Neurology 1981;9(1):97. - PubMed
McAleese 2021
    1. McAleese N, Guzman A, O'Rourke SJ, Gillespie DC. Post-stroke emotionalism: a qualitative investigation. Disability and Rehabilitation 2021;43(2):192-200. - PubMed
Montgomery 1979
    1. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-9. - PubMed
Moore 1997
    1. Moore S, Gresham L, Bromberg M, Kasarkis E, Smith R. A self-report measure of emotional lability. Journal of Neurology, Neurosurgery and Psychiatry 1997;63(1):89-93. - PMC - PubMed
Mukand 1996
    1. Mukand J, Kaplan M, Senno RG, Bishop DS. Pathological crying and laughing: treatment with sertraline. Archives of Physical Medicine and Rehabilitation 1996;77(12):1309-11. - PubMed
Nahas 1998
    1. Nahas Z, Arlinghaus KA, Kotrla KJ, Clearman RR, George MS. Rapid response of emotional incontinence to selective serotonin reuptake inhibitor. Journal of Neuropsychiatry and Clinical Neurosciences 1998;10:453-5. - PubMed
Newsom‐Davis 1999
    1. Newsom-Davis I, Abraham S, Goldstein L, Leigh P. The emotional lability questionnaire: a measure of emotional lability in amyotrophic lateral sclerosis. Journal of the Neurological Sciences 1999;169(1-2):22-5. - PubMed
Page 2021
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. - PMC - PubMed
Panzer 1992
    1. Panzer MJ, Mellow AM. Antidepressant treatment of pathological laughing or crying in elderly stroke patients. Journal of Geriatric Psychiatry and Neurology 1992;5(4):195-9. - PubMed
Poeck 1969
    1. Poeck K. Pathophysiology of emotional disorders associated with brain damage. In: Vinken PJ, Bruyn GW, editors(s). Handbook of Clinical Neurology. Holland: Holland Publishing Co, 1969:343-67.
Review Manager [Computer program]
    1. Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.
Robinson 1993a
    1. Robinson RG, Parikh RM, Lipsey JR, Starkstein SE, Price TR. Pathological laughing and crying following stroke: validation of a measurement scale and a double-blind treatment study. American Journal of Psychiatry 1993;150(2):286-93. - PubMed
Sacco 2008
    1. Sacco S, Sarà M, Pistoia F, Conson M, Albertini G, Carolei A. Management of pathologic laughter and crying in patients with locked-in syndrome: a report of 4 cases. Archives Physical Medicine and Rehabilitation 2008;89(4):775-8. - PubMed
Sandyk 1985
    1. Sandyk R, Gillman MA. Nomifensine for emotional incontinence in the elderly. Clinical Neuropharmacology 1985;8(4):377-8. - PubMed
Schiffer 1983
    1. Schiffer R, Cash J, Herndon R. Treatment of emotional lability with low dosage tricyclic antidepressants. Psychosomatics 1983;24:1094-6. - PubMed
Schünemann 2019
    1. Schünemann HJ, Vist GE, Higgins JP, Santesso N, Deeks JJ, Glasziou P, et al. Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from training.cochrane.org/handbook/archive/v6.
Seliger 1989
    1. Seliger GM, Hornstein A. Serotonin, fluoxetine, and pseudobulbar affect. Neurology 1989;39(10):1400. - PubMed
Sloan 1992
    1. Sloan RL, Brown KW, Pentland B. Fluoxetine as a treatment for emotional lability after brain injury. Brain Injury 1992;6(4):315-9. - PubMed
Smith 2003
    1. Smith AG, Montealegre-Orjuela M, Douglas JE, Jenkis EA. Venlafaxine for pathological crying after stroke. Journal of Clinical Psychiatry 2003;64(6):731-2. - PubMed
Tan 1996
    1. Tan I, Dorevitch M. Emotional incontinence: a dramatic response to paroxetine. Australian and New Zealand Journal of Medicine 1996;26(6):844. - PubMed
Walker 2017
    1. Walker MF, Hoffmann TC, Brady MC, Dean CM, Eng JJ, Farrin AJ, et al. Improving the development, monitoring and reporting of stroke rehabilitation research: Consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. Neurorehabilitation and Neural Repair 2017;31(10-11):877-84. - PubMed
Wolf 1997
    1. Wolf J, Santana H, Thorpy M. Treatment of 'emotional incontinence' with levodopa. Neurology 1997;29:1935-6. - PubMed
Zigmond 1983
    1. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatrica Scandanavica 1983;67(6):361-70. - PubMed

References to other published versions of this review

Allida 2019
    1. Allida S, Patel K, House A, Hackett ML. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No: CD003690. [DOI: 10.1002/14651858.CD003690.pub4] - DOI - PMC - PubMed
Hackett 2010
    1. Hackett ML, Yang M, Anderson CS, Horrocks JA, House A. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews 2010, Issue 2. Art. No: CD003690. [DOI: 10.1002/14651858.CD003690.pub3] - DOI - PubMed
House 2002
    1. House AO, Anderson CS, Hackett ML, Horrocks JA. Interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews 2002, Issue 3. Art. No: CD003690. [DOI: 10.1002/14651858.CD003690] - DOI - PubMed
House 2004
    1. House AO, Hackett ML, Anderson CS, Horrocks JA. Pharmaceutical interventions for emotionalism after stroke. Cochrane Database of Systematic Reviews 2004, Issue 2. Art. No: CD003690. [DOI: 10.1002/14651858.CD003690] - DOI - PubMed

Publication types

Substances